
pmid: 12486751
Abstract A statistical test is proposed for in vitro bioequivalence testing between drug products such as nasal aerosols and nasal sprays. The proposed test generalizes the one recommended in the FDA 1999 guidance to the situation where replicated observations obtained from each sampled canister or bottle of the drug product are available. The technique developed by Hyslop, Hsuan and Holder is used so that the proposed test is asymptotically accurate. The type I error probability and power of the proposed test are investigated through a simulation study. A method for determining the required sample size to achieve a desired power is also proposed. A numerical example is given for illustration. Copyright © 2003 John Wiley & Sons, Ltd.
Aerosols, United States Food and Drug Administration, Statistics as Topic, United States, Pharmaceutical Preparations, Therapeutic Equivalency, Sample Size, Humans, Computer Simulation, Pharmacokinetics, Administration, Intranasal
Aerosols, United States Food and Drug Administration, Statistics as Topic, United States, Pharmaceutical Preparations, Therapeutic Equivalency, Sample Size, Humans, Computer Simulation, Pharmacokinetics, Administration, Intranasal
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 21 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
